Altered exploration and sensorimotor gating of the chakragati mouse model of schizophrenia

Behavioral Neuroscience

Volumn 128, Issue 4, 2014, Pages 460-467

  Young, Jared W ^a,b   Ratty, Anil ^c   Dawe, Gavin S ^d,e   Geyer, Mark A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c Chakra Biotech Pte Ltd   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Animal model; Behavioral pattern monitor; Prepulse inhibition

Indexed keywords

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MOVEMENT; CHAKRAGATI MOUSE; CONTROLLED STUDY; DISEASE MODEL; EXPLORATORY BEHAVIOR; FEMALE; HETEROZYGOTE; HYPERACTIVITY; MALE; MOUSE; MOUSE MODEL; MOUSE STRAIN; NONHUMAN; PREPULSE INHIBITION; SCHIZOPHRENIA; SENSORY GATING; WILD TYPE; ANIMAL; GENETICS; GENOTYPE; MOUSE MUTANT; PHYSIOLOGY; PSYCHOLOGY; SEX DIFFERENCE;

ANIMALS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FEMALE; GENOTYPE; MALE; MICE; MICE, NEUROLOGIC MUTANTS; PREPULSE INHIBITION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS;

EID: 84904741239     PISSN: 07357044     EISSN: 19390084     Source Type: Journal    
DOI: 10.1037/a0036425     Document Type: Article

References (52)

1. Arguello, P. A., & Gogos, J. A. (2010). Cognition in mouse models of schizophrenia susceptibility genes. Schizophrenia Bulletin, 36, 289-300. doi:10.1093/schbul/sbp153
2. Braff, D., Stone, C., Callaway, E., Geyer, M., Glick, I., & Bali, L. (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology, 15, 339 -343. doi:10.1111/j.1469-8986.1978 .tb01390.x
3. Braff, D. L., Swerdlow, N. R., & Geyer, M. A. (1999). Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. The American Journal of Psychiatry, 156, 596-602.
4. Cannon, M., & Jones, P. (1996). Schizophrenia. Journal of Neurology, Neurosurgery & Psychiatry, 60, 604-613. doi:10.1136/jnnp.60.6.604
5. Cross-Disorder Group of the Psychiatric Genomics Consortium; Genetic Risk Outcome of Psychosis (GROUP) Consortium. (2013). Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. The Lancet, 381, 1371-1379. doi:10.1016/ S0140-6736(12)62129-1
6. Dawe, G. S., Nagarajah, R., Albert, R., Casey, D. E., Gross, K. W., & Ratty, A. K. (2010). Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse. Neuroscience, 171, 162-172. doi:10.1016/j.neuroscience.2010.08.061
7. Dawe, G. S., & Ratty, A. K. (2007). The chakragati mouse: A mouse model for rapid in vivo screening of antipsychotic drug candidates. Biotechnology Journal, 2, 1344-1352. doi:10.1002/biot.200700145
8. Fitzgerald, L. W., Miller, K. J., Ratty, A. K., Glick, S. D., Teitler, M., & Gross, K. W. (1992). Asymmetric elevation of striatal dopamine D2 receptors in the chakragati mouse: Neurobehavioral dysfunction in a transgenic insertional mutant. Brain Research, 580, 18-26. doi:10.1016/ 0006-8993(92)90922-V
9. Gard, D. E., Kring, A. M., Gard, M. G., Horan, W. P., & Green, M. F. (2007). Anhedonia in schizophrenia: Distinctions between anticipatory and consummatory pleasure. Schizophrenia Research, 93, 253-260. doi:10.1016/j.schres.2007.03.008
10. Geyer, M. A., Russo, P. V., & Masten, V. L. (1986). Multivariate assessment of locomotor behavior: Pharmacological and behavioral analyses. Pharmacology, Biochemistry and Behavior, 25, 277-288. doi:10.1016/ 0091-3057(86)90266-2
11. Geyer, M. A., & Swerdlow, N. R. (2001). Measurement of startle response, prepulse inhibition, and habituation. Current Protocols in Neuroscience, Chap. 8, Unit 8 7.
12. Halberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A. (2011). Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. Journal of Psychopharmacology, 25, 1548-1561.
13. Halberstadt, A. L., van der Heijden, I., Ruderman, M. A., Risbrough, V. B., Gingrich, J. A., Geyer, M. A., & Powell, S. B. (2009). 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology, 34, 1958 -1967. doi:10.1038/npp .2009.29
14. Harrison, P. J. (1999). The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain, 122, 593-624. doi: 10.1093/brain/122.4.593
15. Henry, B. L., Minassian, A., Young, J. W., Paulus, M. P., Geyer, M. A., & Perry, W. (2010). Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neuroscience and Biobehavioral Reviews, 34, 1296-1306. doi:10.1016/j.neubiorev.2010.04.002
16. Horan, W. P., Subotnik, K. L., Snyder, K. S., & Nuechterlein, K. H. (2006). Do recent-onset schizophrenia patients experience a "social network crisis"? Psychiatry, 69, 115-129.
17. Jones, C. A., Watson, D. J., & Fone, K. C. (2011). Animal models of schizophrenia. British Journal of Pharmacology, 164, 1162-1194. doi: 10.1111/j.1476-5381.2011.01386.x
18. Klaning, U. (1999). Greater occurrence of schizophrenia in dizygotic but not monozygotic twins. Register-based study. The British Journal of Psychiatry, 175, 407-409. doi:10.1192/bjp.175.5.407
19. Levitt, J. J., Bobrow, L., Lucia, D., & Srinivasan, P. (2010). A selective review of volumetric and morphometric imaging in schizophrenia. Current Topics in Behavioral Neuroscience, 4, 243-281. doi:10.1007/ 7854_2010_53
20. Mancuso, F., Horan, W. P., Kern, R. S., & Green, M. F. (2011). Social cognition in psychosis: Multidimensional structure, clinical correlates, and relationship with functional outcome. Schizophrenia Research, 125, 143-151. doi:10.1016/j.schres.2010.11.007
21. Mansbach, R. S., & Geyer, M. A. (1988). Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands. European Journal of Pharmacology, 156, 375-383. doi:10.1016/0014- 2999(88)90283-X
22. Paulus, M. P., & Geyer, M. A. (1991). A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology, 104, 6-16. doi:10.1007/BF02244547
23. Paulus, M. P., & Geyer, M. A. (1993). Three independent factors characterize spontaneous rat motor activity. Behavioural Brain Research, 53, 11-20. doi:10.1016/S0166-4328(05)80262-1
24. Peroutka, S. J., & Synder, S. H. (1980). Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. The American Journal of Psychiatry, 137, 1518-1522.
25. Perry, W., Minassian, A., Henry, B., Kincaid, M., Young, J. W., & Geyer, M. A. (2010). Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Research, 178, 84-91. doi:10.1016/j.psychres.2010.04.032
26. Perry, W., Minassian, A., Paulus, M. P., Young, J. W., Kincaid, M. J., Ferguson, E. J., Geyer, M. A. (2009). A reverse-translational study of dysfunctional exploration in psychiatric disorders: From mice to men. Archives of General Psychiatry, 66, 1072-1080. doi:10.1001/ archgenpsychiatry.2009.58
27. Ratty, A. K., Fitzgerald, L. W., Titeler, M., Glick, S. D., Mullins, J. J., & Gross, K. W. (1990). Circling behavior exhibited by a transgenic insertional mutant. Brain Research. Molecular Brain Research, 8, 355-358. doi:10.1016/0169-328X(90)90050-N
28. Ratty, A. K., Glick, S. D., Mullins, J. J., Fitzgerald, L. W., & Gross, K. W. (1998). US Patent No. 5723719.
29. Ratty, A. K., Matsuda, Y., Elliott, R. W., Chapman, V. M., & Gross, K. W. (1992). Genetic mapping of two DNA markers, D16Ros1 and D16Ros2, flanking the mutation site in the chakragati mouse, a transgenic insertional mutant. Mammalian Genome, 3, 5-10. doi:10.1007/BF00355834
30. Richelson, E., & Souder, T. (2000). Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sciences, 68, 29-39. doi:10.1016/S0024-3205(00)00911-5
31. Risbrough, V. B., Masten, V. L., Caldwell, S., Paulus, M. P., Low, M. J., & Geyer, M. A. (2006). Differential contributions of dopamine D(1), D(2), and D(3) receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology, 31, 2349-2358. doi:10.1038/sj.npp.1301161
32. Schotte, A., Janssen, P. F., Gommeren, W., Luyten, W. H., Van Gompel, P., Lesage, A. S., Leysen, J. E. (1996). Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology, 124, 57-73. doi:10.1007/BF02245606
33. Seeman, P., Lee, T., Chau-Wong, M., & Wong, K. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 261, 717-719. doi:10.1038/261717a0
34. Swerdlow, N. R., Braff, D. L., Taaid, N., & Geyer, M. A. (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Archives of General Psychiatry, 51, 139-154. doi:10.1001/archpsyc.1994.03950020063007
35. Swerdlow, N. R., Weber, M., Qu, Y., Light, G. A., & Braff, D. L. (2008). Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology, 199, 331-388. doi: 10.1007/s00213-008-1072-4
36. Torres, G., Hallas, B. H., Vernace, V. A., Jones, C., Gross, K. W., & Horowitz, J. M. (2004). A neurobehavioral screening of the ckr mouse mutant: Implications for an animal model of schizophrenia. Brain Research Bulletin, 62, 315-326. doi:10.1016/j.brainresbull.2003.09.020
37. Torres, G., Meeder, B. A., Hallas, B. H., Gross, K. W., & Horowitz, J. M. (2005). Preliminary evidence for reduced social interactions in Chakragati mutants modeling certain symptoms of schizophrenia. Brain Research, 1046, 180-186. doi:10.1016/j.brainres.2005.04.015
38. Torres, G., Meeder, B. A., Hallas, B. H., Spernyak, J. A., Mazurchuk, R., Jones, C., Horowitz, J. M. (2005). Ventricular size mapping in a transgenic model of schizophrenia. Brain Research Developmental Brain Research, 154, 35-44. doi:10.1016/j.devbrainres.2004.08.011
39. van den Buuse, M., Ruimschotel, E., Martin, S., Risbrough, V. B., & Halberstadt, A. L. (2011). Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: Implications for schizophrenia. Neuropharmacology, 61, 209-216. doi:10.1016/j.neuropharm.2011.04.001
40. van Os, J., & McGuffin, P. (2003). Can the social environment cause schizophrenia? The British Journal of Psychiatry, 182, 291-292. doi: 10.1192/bjp.182.4.291
41. Verma, V., Tan, C. H., Ong, W. Y., Grigoryan, G. A., Jones, C. A., Stolzberg, D., Dawe, G. S. (2008). The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition. Neuroscience Research, 60, 281-288. doi:10.1016/j.neures.2007.11.007
42. Watanabe, H., Ikeda, M., & Watanabe, K. (1981). Properties of rotational behaviour produced by methylxanthine derivatives in mice with unilateral striatal 6-hydroxydopamine-induced lesions. Journal of Pharmacobio Dynamics, 4, 301-307. doi:10.1248/bpb1978.4.301
43. Wu, Y. C., Hill, R. A., Gogos, A., & van den Buuse, M. (2013). Sex differences and the role of estrogen in animal models of schizophrenia: Interaction with BDNF. Neuroscience, 239, 67- 83. doi:10.1016/j .neuroscience.2012.10.024
44. Young, J. W., & Geyer, M. A. (2011). Using behavioral patterns across species in mood disorder research. In T. D. Gould (Ed.), Mood and anxiety related phenotypes in mice (Vol. 63, pp. 21-41). New York, NY: Humana Press. doi:10.1007/978-1-61779-313-4_2
45. Young, J. W., Goey, A. K., Minassian, A., Perry, W., Paulus, M. P., & Geyer, M. A. (2010a). GBR 12909 administration as a mouse model of bipolar disorder mania: Mimicking quantitative assessment of manic behavior. Psychopharmacology, 208, 443-454. doi:10.1007/s00213- 009-1744-8
46. Young, J. W., Goey, A. K., Minassian, A., Perry, W., Paulus, M. P., & Geyer, M. A. (2010b). The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacology Biochemistry and Behavior, 96, 7-15. doi:10.1016/j.pbb .2010.03.014
47. Young, J. W., Kooistra, K., & Geyer, M. A. (2011). Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology, 36, 1385-1396. doi:10.1038/npp.2011.23
48. Young, J. W., Meves, J. M., Tarantino, I. S., Caldwell, S., & Geyer, M. A. (2011). Delayed procedural learning in alpha7-nicotinic acetylcholine receptor knockout mice. Genes, Brain & Behavior, 10, 720-733. doi: 10.1111/j.1601-183X.2011.00711.x
49. Young, J. W., Powell, S. B., & Geyer, M. A. (2012). Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology, 62, 1381-1390. doi:10.1016/j.neuropharm.2011.06 .013
50. Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M., & Geyer, M. A. (2009). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacology and Therapeutics, 122, 150-202. doi:10.1016/j.pharmthera.2009.02.004
51. Young, J. W., Wallace, C. K., Geyer, M. A., & Risbrough, V. B. (2010). Age-associated improvements in cross-modal prepulse inhibition in mice. Behavioral Neuroscience, 124, 133-140. doi:10.1037/a0018462
52. Young, J. W., Zhou, X., & Geyer, M. A. (2010). Animal models of schizophrenia. In N. R. Swerdlow (Ed.), Behavioral neurobiology of schiozphrenia and its treatment (pp. 391- 433). Berlin, Germany: Springer. doi:10.1007/7854_2010_62